Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Operating Income (2016 - 2025)

Mimedx (MDXG) has disclosed Operating Income for 15 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 90.67% to $21.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.9 million through Dec 2025, up 8.53% year-over-year, with the annual reading at $63.9 million for FY2025, 8.53% up from the prior year.
  • Operating Income hit $21.1 million in Q4 2025 for Mimedx, down from $22.2 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $23.4 million in Q2 2024 to a low of -$9.6 million in Q2 2022.
  • Historically, Operating Income has averaged $6.9 million across 5 years, with a median of $10.9 million in 2023.
  • Biggest five-year swings in Operating Income: plummeted 2250.24% in 2022 and later soared 3981.76% in 2024.
  • Year by year, Operating Income stood at $1.3 million in 2021, then skyrocketed by 780.23% to $11.3 million in 2022, then soared by 36.95% to $15.5 million in 2023, then dropped by 28.64% to $11.1 million in 2024, then skyrocketed by 90.67% to $21.1 million in 2025.
  • Business Quant data shows Operating Income for MDXG at $21.1 million in Q4 2025, $22.2 million in Q3 2025, and $12.4 million in Q2 2025.